Apatinib clinical trials
Also written YN968D1 and Rivoceranib.
How each study uses apatinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the apatinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- YN968D1
- 30
Studies by the year they started
427 studies that test it; most in 2017 (64); 1 more planned to start later
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2009 | 1 |
| 2010 | 3 |
| 2011 | 4 |
| 2012 | 1 |
| 2014 | 1 |
| 2015 | 12 |
| 2016 | 48 |
| 2017 | 64 |
| 2018 | 50 |
| 2019 | 46 |
| 2020 | 52 |
| 2021 | 36 |
| 2022 | 20 |
| 2023 | 17 |
| 2024 | 35 |
| 2025 | 23 |
| 2026 | 13 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 46 · Other 382
Jiangsu HengRui Medicine Co., Ltd. (33) · Sun Yat-sen University (24) · Fudan University (20) · Henan Cancer Hospital (16) · Tianjin Medical University Cancer Institute and Hospital (14) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (13) · Fujian Cancer Hospital (13) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (9)
Often tested with
Tested in the same studies.
Camrelizumab (111) · Adebrelimab (29) · Fluzoparib (19) · Paclitaxel (17) · Etoposide (9) · SHR-1701 (8) · Sintilimab (7) · Albumin-Bound Paclitaxel (7)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 4 phase 3 studies under way
Apatinib is the comparator. A study of two new drugs counts under both.
- 1Tecotabart vedotin · LaNova Medicines Zhejiang Co., Ltd. · next primary completion Nov 2026
- 1Thalidomide · Shanghai Zhongshan Hospital · next primary completion Jun 2030
- 1Capecitabine · Shanghai Zhongshan Hospital · next primary completion Jun 2030
- 1Disitamab vedotin · RemeGen Co., Ltd.
Reaching primary completion within a year · 26, 4 in phase 3
Studies that test apatinib, phase 3 first.
- Dec 2026Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric CancerPhase 2/3 · Ruijin Hospital
- Dec 2026Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCCPhase 2/3 · Guangxi Medical University
- Feb 2027Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast CancerPhase 3 · Fudan University
- Aug 2027Clinical Efficacy of Adebrelimab With or Without Apatinib Mesilate and SOX Neoadjuvant Therapy in Locally Advanced Gastric CancerPhase 3 · Fujian Medical University
- Nov 2026A Random, Non-controlled, Open Clinical Study of Apatinib Mesylate Combined With Albumin-bound Paclitaxel ± Adebrelimab in Treating Advanced Second-line Gastric CancerPhase 2 · The First Affiliated Hospital of Zhengzhou University
- Dec 2026SBRT Combined With Adbelimumab and Apatinib for Perioperative and Conversion Therapy of Hepatocellular CarcinomaPhase 2 · Fujian Cancer Hospital
- Dec 2026Adebrelimab Combined with Apatinib and Gemcitabine and Cisplatin (GP) First-line Treatment for Unresectable Biliary Tract CarcinomaPhase 2 · Henan Cancer Hospital
- Dec 2026Adjuvant Adebrelimab Plus Apatinib for Participants With HCC at High-risk of Recurrence After Curative ResectionPhase 2 · Qilu Hospital of Shandong University
- Dec 2026A Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung CancerPhase 2 · Jin Ying
- Dec 2026Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical CarcinomaPhase 2 · West China Hospital
Studies
Open first, then newest update. How each study uses apatinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 428
- Low-Dose Apatinib Plus Chemotherapy in ADC-Pretreated HER2-Positive and HER2-Low Advanced Breast CancerNot yet recruitingPhase 2Yunnan Cancer HospitalNCT07907354Written as Apatinib mesylate
- A Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCCRecruitingPhase 2/3Guangzhou Virotech Pharmaceutical Co., Ltd.NCT07589244Written as VRT106 in combination with camrelizumab and apatinib
- Application of Intraperitoneal Hyperthermic Chemotherapy in the Treatment of Gastric Cancer With Peritoneal MetastasisNot yet recruitingPhase 2Anhui Provincial Cancer HospitalNCT07904442Written as Retlirafusp alfa + nab-paclitaxel + apatinib
- Retlirafusp Alfa Combined With Zeprumetostat, Apatinib, and Chemotherapy as First-Line Treatment for Metastatic GC/GEJCNot yet recruitingPhase 2Fudan UniversityNCT07874425Written as apatinib
- Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCCRecruitingPhase 2/3Guangxi Medical UniversityNCT05062837Written as Hepatectomy Combined With Camrelizumab and Apatinib
- Individualized Comprehensive Treatment for Advanced Hepatocellular CarcinomaRecruitingNot applicableNanjing Tianyinshan HospitalNCT06893887Written as Apatinib
- A Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung CancerRecruitingPhase 2Jin YingNCT06483282Written as Apatinib Mesylate
- Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric CancerRecruitingPhase 2The First Affiliated Hospital of Bengbu Medical UniversityNCT03219593Written as Apatinib mesylate tablets
- A Clinical Trial With Apatinib for Subjects With Refractory Malignant AscitesRecruitingPhase 2The First Affiliated Hospital of Bengbu Medical UniversityNCT03020979Written as Apatinib
- A Prospective, Single-Arm, Open-Label Clinical Study of the Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined With Targeted Therapy and a PD-1 Inhibitor in Patients With Postoperative Hepatocellular Carcinoma and Microvascular InvasionNot yet recruitingPhase 4Zhai WenlongNCT07790419Written as Donafenib + lenvatinib+apatinib
- Retlirafusp Alfa Plus Apatinib and Chemotherapy as Second-Line Treatment for Pancreatic CancerNot yet recruitingPhase 2Tang-Du HospitalNCT07773363Written as Apatinib
- A Random, Non-controlled, Open Clinical Study of Apatinib Mesylate Combined With Albumin-bound Paclitaxel ± Adebrelimab in Treating Advanced Second-line Gastric CancerRecruitingPhase 2The First Affiliated Hospital of Zhengzhou UniversityNCT07770113Written as Apatinib
- SHR-1701 Plus Apatinib for Second-Line Treatment in Targeted-Immune Pretreated Advanced Hepatocellular CarcinomaNot yet recruitingPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT07749859Written as Retlirafusp alfa Injection, apatinib
- Camrelizumab Combined With Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC)RecruitingPhase 2/3Shanghai Zhongshan HospitalNCT06796803Written as camrelizumab combined with rivoceranib and HAIC
- Precision Medicine for Immunotherapy-Resistant Advanced Esophageal CancerNot yet recruitingPhase 2/3Peking University Cancer Hospital & InstituteNCT07653451Written as Camrelizumab + Apatinib
- A Trial of Apatinib and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable ICCRecruitingPhase 2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT06925516Written as Apatinib and Adebrelimab in Combination With chemotherapy
- Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur, Gimeracil and Oteracil Potassium Capsules for Immune Rechallenge Therapy in Esophageal Squamous Cell CarcinomaRecruitingPhase 2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT06339619Written as Apatinib
- A Multicenter, Randomized, Open-label, Controlled Study of HAIC Combined With Camrelizumab and Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma With High-risk Recurrence FactorsNot yet recruitingNot applicableHenan Cancer HospitalNCT07618546Written as Apatinib Mesylate Tablets
- Retlirafusp Alfa Combined With Apatinib and Nab-Paclitaxel as Second-line Treatment for Gastric or Gastroesophageal Junction CancerNot yet recruitingPhase 2Henan Cancer HospitalNCT07610629Written as Retlirafusp alfa + Apatinib + Nab-paclitaxel
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyRecruitingPhase 2Fudan UniversityNCT05582499Written as Apatinib
See all 428 studies that test apatinib →
Given beside what is tested · 47 — apatinib is usual care or a partner of the new treatment
- GnP Combined With SHR-1701 and Apatinib as First-Line Treatment for Metastatic PDACRecruitingPhase 1/2West China HospitalNCT07802184Written as Apatinib
- Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant TherapyRecruitingPhase 2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT06992336Written as Apatinib, Camrelizumab
- A LM-302 Combination With Other Anti-Tumor Therapies Phase ll StudyRecruitingPhase 2LaNova Medicines Zhejiang Co., Ltd.NCT05934331Written as Apatinib
- Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBCRecruitingPhase 2The First Affiliated Hospital of Bengbu Medical UniversityNCT05192798Written as Apatinib Mesylate
- PDL1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric CancerRecruitingPhase 2The First Affiliated Hospital of Zhengzhou UniversityNCT07294664Written as Apatinib
- SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric CancerRecruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT07464756Written as apatinib
- A Trial of SHR-8068 Combined With Adebrelimab and Apatinib in Perioperative Treatment of Resectable Hepatocellular CarcinomaNot yet recruitingPhase 2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT07682272Written as Apatinib Mesylate Tablets
- ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCCRecruitingPhase 2Peking Union Medical College HospitalNCT07157969Written as Apatinib
- Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular CarcinomaRecruitingPhase 3The First Affiliated Hospital with Nanjing Medical UniversityNCT05613478Written as Apatinib Mesylate
- RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric CancerNot yet recruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT06385873Written as Apatinib
- Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC PatientsRecruitingPhase 2Shanghai Jiao Tong University School of MedicineNCT05069857Written as Apatinib (anti-VEGFR inhibitor)
- Surgical Conversion of Candonilimab (AK104) Plus Paclitaxel, S-1 and Apatinib for Unresectable Advanced G/GEJ CancerRecruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT05853172Written as Apatinib
- Camrelizumab With Apatinib as Neoadjuvant Therapy for Participants With Resectable Non-Small Cell Lung CancerNot yet recruitingPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT04506242Written as Apatinib
- KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 BlockadeActive, not recruitingPhase 2Peking University Cancer Hospital & InstituteNCT06099821Written as Apatinib
- AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2Active, not recruitingPhase 3AstraZenecaNCT06346392Written as Apatinib
- A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC)CompletedPhase 2Jiangsu HengRui Medicine Co., Ltd.NCT03083041Written as Apatinib
- A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTCCompletedPhase 2Jiangsu HengRui Medicine Co., Ltd.NCT03092895Written as Apatinib
- Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric CancerActive, not recruitingPhase 2Ruijin HospitalNCT06693128Written as Apatinib
- Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized TrialActive, not recruitingPhase 3Sun Yat-sen UniversityNCT05198609Written as Apatinib
- A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic TherapyCompletedPhase 3Jiangsu HengRui Medicine Co., Ltd.NCT03813784Written as Apatinib
Showing 20 of 47.
As the comparator · 5 — what is tested is compared with apatinib
- A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunotherapy in Unresectable Hepatocellular CarcinomaNot yet recruitingPhase 2/3Shanghai Zhongshan HospitalNCT07309419Written as Apatinib
- Camrelizumab and Apatinib With or Without FOLFOX Chemotherapy for Advanced HCCRecruitingPhase 3Linhui PengNCT07267806Written as Camrelizumab and apatinib
- A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-OverexpressionRecruitingPhase 3RemeGen Co., Ltd.NCT04714190Written as Apatinib Mesylate Tablets
- LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma.Active, not recruitingPhase 3LaNova Medicines Zhejiang Co., Ltd.NCT06351020Written as Apatinib
- A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC)TerminatedPhase 3Jiangsu HengRui Medicine Co., Ltd.NCT04985136Written as Rivoceranib
What changed recently
From the registry's own updates since Oct 18, 2026.
Newly registered2
Codes
What other systems call apatinib · ClinicalTrials.gg INT005736
- MeSH (NLM) C553458apatinibConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 5S371K6132RIVOCERANIBConfirmed FDA, NLM, Wikidata
- Wikidata Q27262801apatinibConfirmed FDA, NLM, Wikidata
- DrugBank DB14765One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C553458 | apatinib | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 5S371K6132 | RIVOCERANIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27262801 | apatinib | Confirmed FDA, NLM, Wikidata |
| DrugBank | DB14765 | — | One source Wikidata |
Also registered as rivoceranib mesylate (UNII TK02X14ASJ).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.